A preclinical model to assess the antigenicity of an HLA-A2 melanoma cell vaccine.

doi:10.1002/1097-0142(19930801)72:3<750::aid-cncr2820720319>3.0.co;2-v

Back to search

Article

A preclinical model to assess the antigenicity of an HLA-A2 melanoma cell vaccine.

Cancer - 1 Aug 1993

Hayashi Y, Hoon D S, Foshag L J, Park M S, Terasaki P I, Morton D L

Abstract excerpt

BACKGROUND: The authors have demonstrated that immunization with melanoma whole-cell vaccine (MCV) augments T-cell responses to melanoma and that cytotoxic T-cells (CTL) recognize allogeneic melanoma-bearing shared HLA-A antigens. A preclinical model was developed to assess CTL activation in vitr...

Topics

Antigens, Neoplasm
Cell Line
Cytotoxicity, Immunologic
HLA-A2 Antigen
Humans
Immunotherapy
Lymphocyte Activation
Melanoma
Phenotype
T-Lymphocytes, Cytotoxic
Tumor Cells, Cultured
Vaccines

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.